Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
NCT03439865Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in chronic rhinosinusitis (CRS) comparing standard of care treatment + ivacaftor with standard of care treatment (2 arms). Primary endpoint: Improvement in quality of life measures at 30 days. Started May 2019; status: recruiting.
02
Drugs
ivacaftor
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03439865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439865.